Iannazzone Silvia S, Ingordo Vito
Outpatient Department of Dermatology, Benevento North-East District, Local Health Unit Benevento, Benevento, Italy.
Outpatient Department of Dermatology, District n. 6, Local Health Unit Taranto, Taranto, Italy.
Dermatol Pract Concept. 2018 Apr 30;8(2):129-131. doi: 10.5826/dpc.0802a12. eCollection 2018 Apr.
Surgical excision is the first-choice treatment for basal cell carcinoma (BCC). Other treatments with topical agents such as 5-fluorouracil or imiquimod have also been suggested for use in superficial BCC (sBCC). Ingenol mebutate (IM) is a novel agent employed in the treatment of superficial actinic keratoses. The drug has been also successfully used in the treatment of sBCC. A case of large nodular BCC (nBCC) of the face in a 100-year-old inoperable woman is described. IM 0.015% gel was applied once daily for three consecutive days. This dose regimen was repeated for seven rounds within 11 months, with complete cure of the tumor. Mild local skin reactions, which were tolerated well, were observed. Selected cases of nBCC could be treated with IM gel, but the optimal concentration of the drug and the standard dose regimen of treatment are yet to be determined.
手术切除是基底细胞癌（BCC）的首选治疗方法。也有人建议使用5-氟尿嘧啶或咪喹莫特等外用药物治疗浅表性基底细胞癌（sBCC）。鬼臼毒素（IM）是一种用于治疗浅表性光化性角化病的新型药物。该药物也已成功用于治疗sBCC。本文描述了一名100岁无法手术的女性面部巨大结节性基底细胞癌（nBCC）的病例。每天一次涂抹0.015%的IM凝胶，连续三天。该剂量方案在11个月内重复七轮，肿瘤完全治愈。观察到有轻微的局部皮肤反应，但耐受性良好。部分nBCC病例可用IM凝胶治疗，但药物的最佳浓度和标准治疗剂量方案尚待确定。
